Browse > Article

Synthesis and In Vitro Cytotoxicity of 1,3-Dioxoindan-2-Carboxylic Acid Arylamides  

Jung, Jae-Kyung (College of Pharmacy, Chungbuk National University)
Ryu, Jin-Hyeong (College of Pharmacy, Chungbuk National University)
Yang, Sung-Il (College of Medicine, Kunkuk University)
Cho, Jung-Sook (College of Medicine, Dongguk University)
Lee , Hee-Soon (College of Pharmacy, Chungbuk National University)
Publication Information
Archives of Pharmacal Research / v.27, no.10, 2004 , pp. 997-1000 More about this Journal
Abstract
A series of 1,3-dioxoindan-2-carboxylic acid arylamides were synthesized and evaluated for in vitro cytotoxicity against four human cancer cell lines (HOP62, SK-OV-3, MD-MB-468 and T- 47D). The most active was compound 3e (1.2 ${\mu}M$ against SK-OV-3 cell line) bearing a 4- methyl substituent.
Keywords
Antitumor agents; Cytotoxic activity; TAS-103;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Cortes, F. and Pinero, J., Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemather. Pharmacal., 34, 411-415(1994)   DOI   ScienceOn
2 Dittrich, C., Coudert, B., Paz-Ares, L., Caponigro, F., Salzberg, M., Gamucci,T., Paoletti, X., Hermans,C., and Lacombe, D., Fumoleau P. and on behalf of the European Organization for Research and Treatment of CancerEarly Clinical Studies Group/New Drug Development Programme(EORTC-ECSG/ NDDP), Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. European J. Cancer, 39,330-334 (2003)   DOI   ScienceOn
3 Lee, H., Lee, J., Hong, S-. S., Yang, S-. I., Jung, S.-H., Jahng, Y., and Cho, J., Synthesis and in vitro cytotoxicity of 2-alkylaminosubstituted quinoline derivatives. Arch. Pharm. Res., 23, 450-454 (2000)   DOI   ScienceOn
4 Skehan, P., Storeng, R., Scudiero, D, Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990)   DOI   PUBMED
5 Bonner, J. A. and Kozelsky, T. F., The significance of the sequence of administration of topotecan and etoposide. Cancer Chemather. Pharmacal., 39, 109-112 (1996)   DOI   ScienceOn
6 Minderman, H., Wrzosek, C., Cao, S. S., Utsugi,T., Kobunai, T., Yamada, Y, and Rustum, Y. M., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemather. Pharmacal., 45, 78-84 (2000)and references cited therein.   DOI   ScienceOn
7 Lee, H., Lee, J., and Yang, S-I., Synthesis and in vitro cytotoxicity of 4-alkyl- or 4-arylaminosubstituted cyclopenta [c]quinoline derivatives. Arch. Pharm. Res., 24, 385-389 (2001)   DOI   ScienceOn
8 Baguley, B. C., Zhuang, L., and Marshall, E. M., Experimental solid tumor activity of N-[2-(dimethylamino)-ethyl] acridine-4-carboxamide. Cancer Chemather. Pharmacal., 36, 244-248 (1995).   DOI   ScienceOn
9 Kaslow, C. E. and Sommer, N. B., SubstitutedLepidines. J. Am. Chem. Soc., 68, 644-646(1946)   DOI
10 Aoyagi, Y., Kobunai, T., Utsugi, T., Oh-hara, T., and Yamada, Y., In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Jpn. J. Cancer Res., 90, 578-587, (1999) and references cited therein   DOI   PUBMED
11 Atwell, G. J., Rewcastle, G. W., Baguley, B. C., and Denny, W. A., Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem., 30, 664-669(1987).   DOI   PUBMED
12 Potts, K. T., Bhattachaarjee, D., and Walsh E. B., Cycloaddition routes to azaanthraquinone derivatives. 1. use of azadienophiles. J. Org. Chem., 51, 2011-2021 (1986)   DOI